| Source: |
| Type: |
| PD-L1 is a protein that plays a crucial role in the regulation of the immune system.
PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection. PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors. PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype. PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers. |
| Lung CSC (Cancer Stem Cells) markers (CD133, CD44, ALDHA1, Nanog and Oct4) |
| 1030- | BBR, | Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5 |
| - | in-vitro, | Lung, | H460 |
| 1022- | EDM, | Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis |
| - | in-vivo, | Lung, | H1975 | - | in-vitro, | Lung, | H1650 |
| 1036- | EGCG, | Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | LU99 |
| 997- | GA, | The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H292 | - | in-vitro, | Nor, | HUVECs |
| 1021- | HNK, | Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer |
| - | in-vivo, | Lung, | NA |
| 1025- | LT, | Api, | Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer |
| - | in-vivo, | Lung, | NA |
| 1042- | MEL, | Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | LLC1 |
| 1044- | Myr, | Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells |
| - | in-vitro, | Lung, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:15 Cells:% prod#:% Target#:243 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid